Stroke Clinical Trials

Find Stroke Clinical Trials Near You

Clinical Impact of the Use of IMPROVE for Selection of Patients for Carotid Revascularisation: a Randomized Controlled Multicentre Non-inferiority Trial in Symptomatic Patients With 30-99% Carotid Stenosis

Status: Recruiting
Location: See all (10) locations...
Intervention Type: Other
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Narrowing of the carotid artery due to atherosclerosis with an unstable plaque can cause a stroke. Patients with carotid artery disease who have had a TIA or minor stroke and are at high risk of another stroke are often treated with surgery or stenting to remove the plaque. For lower-risk patients, medication alone is the better option, as surgery also carries risks. A new decision method, based on MRI detection of unstable plaques (IMPROVE), can better assess stroke risk and help determine which patients do or do not need surgery. We are investigating whether this method is at least as effective as the standard approach, which mainly considers the degree of narrowing. We expect that this new method will help reduce strokes and lower healthcare costs. Patients will be followed for several years to compare which method is better for health and costs.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Mentally competent

• 18 years or older

• Recent (\<30 days) stroke (modified Rankin scale ≤3) or TIA

• Ipsilateral 30-99% atheromatous stenosis at the carotid bifurcation assessed using non-invasive imaging according to NASCET criteria

• Life expectancy \>5 years

• Patient and stenosis are suitable for carotid revascularisation

• Patient is agreeable to randomisation and willing to accept either IMPROVE-based or CAU-based selection method for carotid revascularisation

Locations
Other Locations
Netherlands
Amsterdam UMC
NOT_YET_RECRUITING
Amsterdam
Rijnstate
NOT_YET_RECRUITING
Arnhem
Albert Schweitzer Ziekenhuis
NOT_YET_RECRUITING
Dordrecht
Zuyderland
NOT_YET_RECRUITING
Heerlen
Maastricht University
RECRUITING
Maastricht
Radboud UMC
NOT_YET_RECRUITING
Nijmegen
Erasmus MC
NOT_YET_RECRUITING
Rotterdam
Haaglanden MC
NOT_YET_RECRUITING
The Hague
Utrecht UMC
NOT_YET_RECRUITING
Utrecht
Isala
NOT_YET_RECRUITING
Zwolle
Contact Information
Primary
M. Eline Kooi, Prof. dr.
improve.trial@mumc.nl
+31 43 387 4911
Backup
Robin M.M. Pleumeekers, MSc.
robin.pleumeekers@mumc.nl
+31 43 387 7622
Time Frame
Start Date: 2026-03-31
Estimated Completion Date: 2031-08-31
Participants
Target number of participants: 613
Treatments
No_intervention: Care As Usual (CAU)
CAU follows Dutch FMS guidelines, recommending revascularisation for symptomatic patients with ≥50% stenosis and OMT-only for 30-49%. Guidelines suggest risk models like CAR score but lack treatment guidance.
Experimental: Intervention (IMPROVE) Arm:
IMPROVE recommends revascularisation + OMT for patients with ≥10% 3-year ipsilateral stroke risk according to the IMPROVE-score and OMT-only for those with lower than 10% risk.
Sponsors
Collaborators: UMC Utrecht, Academisch Ziekenhuis Maastricht, Albert Schweitzer Hospital, Amsterdam UMC, Zuyderland Medical Centre, Isala, Radboud University Medical Center, Erasmus Medical Center, Haaglanden Medical Centre, Rijnstate Hospital
Leads: Maastricht University Medical Center

This content was sourced from clinicaltrials.gov